Create Free Account

By creating account you will get access to hot stocks & personalised emails

Memphasys Ltd

Healthcare AU MEM

0.006AUD
-(-%)

Last update at 2024-12-19T01:16:00Z

Day Range

0.0050.006
LowHigh

52 Week Range

0.0040.01
LowHigh

Fundamentals

  • Previous Close 0.006
  • Market Cap10.58M
  • Volume259554
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-3.79839M
  • Revenue TTM1.09M
  • Revenue Per Share TTM0.001
  • Gross Profit TTM 0.62M
  • Diluted EPS TTM-

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -3.40262M -2.08196M -1.48643M -1.13388M -1.04458M
Minority interest - - - - -
Net income -3.40262M -2.08196M -1.48643M -0.97641M -1.09191M
Selling general administrative 0.58M 1.09M 1.24M 1.15M 0.89M
Selling and marketing expenses 0.15M 0.11M - - -
Gross profit 0.00922M 0.00824M 0.00824M - -
Reconciled depreciation 0.61M 0.12M 0.26M 0.20M 0.00892M
Ebit -3.08584M -1.62931M -1.46109M -1.45796M -0.99724M
Ebitda -2.47300M -1.50609M -1.20161M -1.26173M -0.98832M
Depreciation and amortization 0.61M 0.12M 0.26M 0.20M 0.00892M
Non operating income net other - - - - -
Operating income -2.76149M -1.96653M -1.46109M -1.45796M -0.99724M
Other operating expenses 3.60M 2.05M 1.96M 1.46M 1.09M
Interest expense 0.32M 0.45M 0.03M 0.04M 0.05M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.39M 0.00071M 0.00254M 0.03M 0.00288M
Net interest income -0.41494M -0.56597M -0.08697M -0.06860M -0.04446M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.96M 1.67M 0.33M -0.15747M 0.05M
Total revenue 0.02M 0.03M 0.03M 0.00000M 0.00000M
Total operating expenses 3.64M 2.74M 1.96M 1.46M 1.09M
Cost of revenue 0.00615M 0.02M 0.02M - -
Total other income expense net 0.65M 1.22M 0.30M 0.32M -0.04733M
Discontinued operations - - - - -
Net income from continuing ops -3.40262M -2.08196M -1.48643M -1.13388M -1.04458M
Net income applicable to common shares -3.40262M -2.08196M -1.48643M -1.13388M -1.04458M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 12.43M 14.67M 14.12M 14.58M 11.30M
Intangible assets - 10.29M 9.68M 8.29M 6.55M
Earning assets - - - - -
Other current assets 1.18M 1.36M 1.55M 1.57M 1.39M
Total liab 5.59M 7.28M 6.47M 5.97M 1.54M
Total stockholder equity 6.84M 7.38M 7.65M 8.61M 9.76M
Deferred long term liab - - - - -
Other current liab 0.24M 5.45M 4.41M 0.70M -0.00301M
Common stock 57.28M 53.42M 50.34M 48.88M 48.70M
Capital stock - 53.42M 50.34M 48.88M 48.70M
Retained earnings -50.43009M -46.17323M -42.77061M -41.16742M -39.68099M
Other liab - 0.00136M 0.03M 0.03M 0.03M
Good will - - - - -
Other assets - - - - -
Cash 0.28M 0.64M 0.27M 2.00M 1.97M
Cash and equivalents - - - - -
Total current liabilities 5.25M 5.57M 4.54M 0.86M 0.59M
Current deferred revenue 0.07M -4.65768M -3.65939M -0.26886M 0.23M
Net debt 4.48M 5.73M 5.29M 3.35M -0.90056M
Short term debt 4.42M 4.66M 3.66M 0.27M 0.14M
Short long term debt - 4.55M 3.56M 0.18M 0.03M
Short long term debt total 4.76M 6.37M 5.56M 5.36M 1.07M
Other stockholder equity -0.01245M -7.24456M -7.57033M -7.71675M -9.01675M
Property plant equipment - 2.10M 2.34M 2.60M 1.19M
Total current assets 1.62M 2.25M 2.03M 3.69M 3.56M
Long term investments - 0.03M 0.07M - -
Net tangible assets - -2.91005M -2.03224M 0.32M 3.21M
Short term investments - 0.04M - - -
Net receivables - 0.12M 0.12M 0.01M 0.17M
Long term debt - - 0.08M 3.16M -
Inventory 0.16M 0.13M 0.09M 0.12M 0.03M
Accounts payable 0.52M 0.12M 0.13M 0.16M 0.22M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 0.14M 0.08M 0.89M 0.74M
Additional paid in capital - - - - -
Common stock total equity - - - - 48.70M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 10.09M -12.41911M -12.09258M -10.89206M -7.74085M
Deferred long term asset charges - - - - -
Non current assets total 10.81M 12.42M 12.09M 10.89M 7.74M
Capital lease obligations - 1.83M 1.92M 2.01M 1.04M
Long term debt total - 1.71M 1.83M 4.86M 0.93M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -1.97670M -3.07778M -3.00155M -3.11031M -2.12369M
Change to liabilities -0.00426M 1.89M 1.41M 1.23M 1.09M
Total cashflows from investing activities -1.97670M -3.07778M -3.00155M -3.11031M -2.12369M
Net borrowings 0.68M -0.01317M 2.81M -0.09227M 1.18M
Total cash from financing activities 3.75M 1.03M 2.99M 4.11M 3.50M
Change to operating activities 1.93M 0.86M 0.09M 0.17M -0.00538M
Net income -3.40262M -2.08196M -1.48643M -1.13388M -1.09191M
Change in cash 0.37M -1.73384M 0.04M 1.09M 0.67M
Begin period cash flow 0.27M 2.00M 1.97M 0.87M 0.20M
End period cash flow 0.64M 0.27M 2.00M 1.97M 0.87M
Total cash from operating activities -1.40667M -0.36885M 0.04M 0.09M -0.70747M
Issuance of capital stock 3.36M 1.08M 0.19M 4.54M 2.70M
Depreciation 0.12M 0.12M 0.26M 0.20M 0.00892M
Other cashflows from investing activities -0.15467M -0.15467M 0.00254M 0.03M 0.00288M
Dividends paid 0.85M 0.07M 2.97M 0.07M -
Change to inventory -0.04370M 0.03M -0.08612M -0.03268M -0.03268M
Change to account receivables - - - -0.27727M -0.62058M
Sale purchase of stock -0.28357M -0.03053M -0.00613M -0.33990M -0.38003M
Other cashflows from financing activities 1.60M -0.01317M 5.84M -0.09227M 1.34M
Change to netincome -0.49708M -0.54806M -0.14158M -0.05104M -0.12855M
Capital expenditures 1.82M 2.92M 3.00M 3.14M 2.13M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.04370M 0.03M -0.08612M -0.03268M 0.59M
Stock based compensation 0.09M 0.07M 0.14M 0.28M -
Other non cash items 1.88M 1.59M 1.27M 1.03M 1.04M
Free cash flow -3.22870M -3.29197M -2.95939M -3.04489M -2.12656M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MEM
Memphasys Ltd		 - -% 0.006 - - 9.71 1.55 251.83 -11.1564
CSL
CSL Ltd		 -3.45 1.22% 278.79 32.86 33.00 9.11 5.02 6.65 20.64
TLX
Telix Pharmaceuticals Ltd		 -0.07 0.27% 25.67 161.73 75.19 12.58 19.98 12.52 109.28
MSB
Mesoblast Ltd		 1.07 54.04% 3.05 - 454.55 312.43 2.49 67.90 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.36 2.79% 12.54 13.51 35.21 8.91 5.13 6.48 8.45

Reports Covered

Stock Research & News

View All

Profile

Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company primarily develops Felix, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid oxidative stress assay; and AI-Port. In addition, the company offers ambient temperature storage product for human sperm. Memphasys Limited was incorporated in 2006 and is based in Homebush, Australia.

Memphasys Ltd

34 Richmond Road, Homebush, NSW, Australia, 2140

Key Executives

Name Title Year Born
Ms. Alison Mary Coutts B.E., B.E. (Chem), GDipBiotech, M.B.A., MBA MD, CEO & Director NA
Pablo Neyertz Director of Fin. NA
Nick Gorring Operations Mang. NA
Mr. Malcolm Coleman Chief Financial Officer of Nusep Ltd NA
Mr. Andrew Metcalfe B.Bus, CPA, FGIA, MAICD Company Sec. NA
Dr. David Ali Acting CEO & Executive Director NA
Pablo Neyertz Director of Finance NA
Associate Prof. Hassan Bakos Director of Operations NA
Prof. R. John Aitken Ph.D., ScD FRSE Scientific Director NA
Mr. Andrew Metcalfe B.Bus, CPA, FGIA, MAICD Company Secretary NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.